Corgentech Phase 2 Trial as respects algrx 4975 meets caucus Endpoint about decreased Pain cause tendonitis Patients.
. (Nasdaq: CGTK) today diffused positive neurological data from a form 2clinical assay exhibitive that ALGRX 4975-one of three non-opioid woe managementdrug candidates the company is developing-demonstrated sustained,statistically significant pain fill-in over placebo in favor patients amidst tendonitisof the elbow. Click link up being supplementary info. . . CorgentechInc.